메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

ASEAN Foundation introduced CALM MRI: Children and the No Longer Scary Machine

SINGAPORE, Feb. 27, 2026 -- The ASEAN Foundation organized the regional programme "CALM MRI – Fear to Confidence: Learning through Play with LEGO MRI Kits Programme", implemented across Indonesia and Singapore. The initiative serves as a platform to present the programme's outcomes, which aim to help children better understand Magnetic Resonance Imaging (MRI) procedures through a play-based learning approach. Designed to reduce anxiety and build familiarity, CALM MRI introduces children to the MRI process using specially designed LEGO® MRI kits. By transforming a
- 김갑성 기자
- 2026-02-27 12:39
Basecare Medical (HK.2170) Receives NMPA Approval for Core Product Geri Medium, Unlocking New Opportunities in Assisted Reproduction

SUZHOU, China, Feb. 27, 2026 -- Basecare Medical (02170.HK) has recently encountered a key catalyst——its Gems one-step embryo culture medium has officially obtained the China Class III Medical Device Registration Certificate (National Medical Products Administration Registration No. 20253180071). This represents a core signal of the company's strategic transformation implementation and accelerated domestic substitution layout, and is expected to become an important driver for its valuation repair, warranting close attention. From a market logic perspective, the approval of this product
- 김갑성 기자
- 2026-02-27 10:49
Cynosure Lutronic bolsters its strength in APAC -- The world's fastest-growing medical aesthetics device region, with dual regulatory approvals for the Clarity II™ in China and Japan, February 2026

SINGAPORE, Feb. 27, 2026 -- Cynosure Lutronic, a global leader in energy-based medical aesthetic devices, announced today that Clarity II, its dual-wavelength long-pulse laser platform, has received regulatory approval in China and Japan. This marks a significant expansion of the company's clinically approved laser portfolio across two of Asia's most highly regulated aesthetic markets. "The approval enables the introduction of a single, integrated dual wavelength laser platform designed to support multiple treatment indications and diverse patient profiles and is
- 김갑성 기자
- 2026-02-27 10:33
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics

[ 메디채널 김갑성 기자 ] TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in detecting rare genetic diseases 40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 27, 2026 -
- 김갑성 기자
- 2026-02-27 08:00
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference

SUZHOU, China, Feb. 27, 2026 -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects of BCG therapy itself, means that a substantial number of patients cannot access effective BCG treatment. Therefore, it is essential to seek better alternative therapies to BCG in order to meet clinical needs. Based on this, ImmVira Group is further expanding the clinical trial of its core oncolytic virus product, MVR-T3011—
- 김갑성 기자
- 2026-02-27 08:00
메디트, 세계 여성의 날 기념 'Glow Together' 캠페인 전개

서울, 대한민국 2026년 2월 26일 -- 디지털 덴티스트리 솔루션 분야의 글로벌 기업 메디트(Medit)는 오는 3월, 세계 여성의 날을 기념하는 글로벌 캠페인 'Glow Together'를 시작한다고 밝혔다. 'Glow Together'는 메디트의 여성 임직원들이 작은 실천에서 출발해, 나눌수록 더욱 강해지는 '빛'의 의미를 확장하자는 취지에서 시작됐다. 세계 여성의 날의 정신을 바탕으로 기획된 이번 캠페인은 전 세계 치과 커뮤니티 간의 연결을 촉진하고, 참여가 실제 사회적 가치로 이어지도록 설계됐다. 여성의 영향력에서 영감을 받았지만, 'Glow Together'는 성별과 관계없이 목적 있는 행동에 함께하고자 하는 모든 치과 전문인을 대상으로 진행된다. 캠페인 세부 내용, 참여 자격 및 등록 방법은 아래 페이지에서 확인할 수 있다.https://www.medit.com/glow_together/ 함께 나누는 빛에서 시작된 'Glow Together' 캠페인 'Glow Together'는 메디트 여성 구성원들의 내부 논의에서 출발했다. 작은 행동이라도 함께할
- 김갑성 기자
- 2026-02-27 08:00
Waters, MaxPeak Premier 기술 기반 차세대 Microflow LC 컬럼 출시, 적은 시료 및 용매 소비량으로 더 높은 감도 구현

헤드라인: 스테인리스 Microflow 컬럼 대비 최대 2배 높은 감도를 제공해 고처리량 바이오분리, DMPK 및 오믹스 응용 분야 전반에서 검출 및 정량 한계를 낮출 수 있습니다. 2.1mm I.D. 컬럼 대비 최대 75% 시료 소비량 절감으로 세포 및 유전자 치료제와 맞춤 의약품 후보물질 등 귀중한 물질을 보존하는 동시에 보다 심층적인 분석 정보를 제공합니다. 2.1mm I.D. 컬럼 대비 최대 4배 용매 소비량 절감으로 실험실의 지속가능성 목표를 달성하고, 운영 비용을 절감하며 성능 저하 없이 결과 도출 시간을 단축할 수 있도록 지원합니다. 매사추세츠주 밀포드, 2026년 2월 27일 -- Waters Corporation (NYSE: WAT)은 오늘 Waters의 ACQUITY™, BioResolve™, GTxResolve™ 컬럼 브랜드에 적용된 MaxPeak™ Premier 기술 기반 1mm I.D. 액체 크로마토그래피(LC) 컬럼을 출시했다고 발표하였습니다. 이 새로운 Microflow 컬럼은 감도를 향상시키는 동시에 용매와 시료 낭비를 줄여주어 바이오분석, 신약 발견 및 개발, 대사체학,
- 김갑성 기자
- 2026-02-27 07:00
Optellum Secures TGA Approval to Expand AI-Enabled Lung Nodule Solution To Australia

OXFORD, England, Feb. 27, 2026 -- Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration (TGA) class IIb approval in Australia for the Virtual Nodule Clinic (VNC) platform to support early lung cancer diagnosis. This important regulatory milestone was achieved after a rigorous review of technical documentation and validation studies, recognizing its safety and performance for clinical use. VNC helps identify, triage, and manage patients with pulmonary nodules, and includes a clinically
- 김갑성 기자
- 2026-02-27 05:01
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated Study is expected to
- 김갑성 기자
- 2026-02-27 04:34
ArisGlobal Launches NavaX Translation to Eliminate Manual Translation in Global Pharmacovigilance

Strategic partnership with TransPerfect Life Sciences embeds certified, pharma-grade translation directly into LifeSphere Safety workflows BOSTON, Feb. 26, 2026 -- ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, recently announced the launch of NavaX Translation, a new solution delivered through a strategic partnership with TransPerfect Life Sciences. NavaX Translation brings certified, pharma-grade translation and multilingual content directly into LifeSphere Safety workflows, enabling faster, more accurate, and full
- 김갑성 기자
- 2026-02-26 22:12

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 02일 23시 00분